CONTEPO
Launchfosfomycin disodium
NDAINTRAVENOUSPOWDERPriority Review
Approved
Oct 2025
Lifecycle
Launch
Competitive Pressure
0/100
Data completeness
4/8 — Partial
Priority Review
CONTEPO (fosfomycin disodium) is [ see microbiology () ] . First approved in 2025.
Drug data last refreshed 6h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CONTEPO is an intravenous fosfomycin disodium powder antibiotic approved in October 2025. It is a cell wall-active agent that inhibits bacterial peptidoglycan synthesis, with a broad spectrum mechanism of action. The product targets serious bacterial infections in hospitalized patients requiring IV antimicrobial therapy.
Launch12.6 years to LOE
Early-stage launch product with minimal competitive pressure; commercial team focused on market penetration, hospital formulary access, and infection specialist education.
Mechanism of Action
[ see Microbiology () ] .
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CONTEPO positions you in a launch-stage, high-growth opportunity with minimal competitive distraction and strong patent protection extending 12+ years. This is an ideal career move for professionals seeking to build a product from market entry through peak sales with strategic flexibility and visibility.
Brand ManagerProduct Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.